白癜风患者黑素细胞移植的疗效与白介素6、可溶性白介素6受体水平的关系

【摘要】 目的 探讨白介素6（IL-6）、可溶性白介素6受体（sIL-6R）与白癜风患者自体培养黑素细胞移植疗效的关系。 方法 对53例稳定期白癜风患者进行自体培养黑素细胞移植，收集白斑区与非白斑区的疱液，移植后6个月观察疗效，用ELISA的方法测定白癜风患者皮肤组织液中IL-6及sIL-6R水平，比较移植成功组与失败组白斑区及非白斑区组织液中IL-6及sIL-6R水平。 结果 白癜风患者白斑区IL-6（113.22 ± 81.20） ng/L与非白斑区（84.40 ± 48.78） ng/L，及白斑区sIL-6R（56.28 ± 24.87） ng/L和非白斑区（53.96 ± 25.67） ng/L配对比较，差异有统计学意义。移植失败组与成功组比较：白斑区IL-6（153.61 ± 100.26） ng/L的浓度明显高于移植成功组（88.75 ± 55.75） ng/L（P < 0.05）；非白斑区浓度（100.26 ± 55.17） ng/L与（74.78 ± 42.50） ng/L比较，差异无统计学意义，两组之间sIL-6R的浓度比较，差异均无统计学意义。稳定时间 < 1年的白斑区IL-6（148.46 ± 88.00） ng/L与非白斑区（114.82 ± 64.66） ng/L均高于稳定时间 ≥ 1年的白斑区（93.54 ± 71.07） ng/L与非白斑区（67.40 ± 25.23） ng/L（P < 0.05），而sIL-6R比较，差异无统计学意义。节段型白斑区IL-6（77.33 ± 61.70） ng/L明显低于非节段型（131.68 ± 84.54） ng/L（P < 0.05），非白斑区IL-6及sIL-6R的组间比较，差异均无统计学意义。非节段型患者的移植成功组非白斑区IL-6（78.25 ± 40.30） ng/L、白斑区（96.27 ± 53.390） ng/L与失败组非白斑区（107.02 ± 42.48） ng/L、白斑区（178.90 ± 96.48） ng/L比较，差异均有统计学意义，sIL-6R在两组间比较，差异无统计学意义。 结论 IL-6在组织液中的异常表达对白癜风患者皮损区的微环境改变有一定的影响，可能与自体黑素细胞移植疗效相关。

Efficacy of autologous cultured melanocyte transplantation for and its relationship with the levels of interleukin-6 and soluble interleukin-6 receptor in suction blister fluid from patients with vitiligo

Tang Huijuan*, Zhou Miaoni, Fu Lifang, Hong Weisong, Wei Xiaodong, Zheng Dongdi, Xu Aie. *Hangzhou Clinical College Affiliated to Anhui Medical University, Hangzhou 310009, China Corresponding author: Xu Aie, Email: xuaiehz@msn.com 【Abstract】 Objective To investigate the relationship between the efficacy of autologous cultured melanocyte transplantation for and the levels of interleukin-6 （IL-6） and soluble IL-6 receptor （sIL-6R） in suction blister fluid from patients with vitiligo. Methods Fifty-three patients with stable vitiligo were included in this study, and received autologous cultured melanocyte transplantation. Clinical efficacy was evaluated at six months after the transplantation. Suction blister fluid was collected from vitiliginous and non-vitiliginous skin in these patients before and six months after the transplantation. Enzyme-linked immunosorbent assay（ELISA） was performed to measure the levels of IL-6 and sIL-6R in the blister fluid. Statistical analysis was done using paired t test and two independent samples t-test. Results Significant differences were observed in the blister fluid levels of IL-6 （（113.22 ± 81.20） vs. （84.40 ± 48.78） ng/L, P < 0.01） and sIL-6R （（56.28 ± 24.87） vs. （53.96 ± 25.67） ng/L, P < 0.05） between vitiliginous and non-vitiliginous skin. The unsuccessfully treated patients showed higher levels of IL-6 in vitiliginous skin （（153.61 ± 100.26） vs. （88.75 ± 55.75） ng/L, P < 0.05） but similar levels of IL-6 in non-vitiliginous skin （（100.26 ± 55.17） vs. （74.78 ± 42.50） ng/L, P > 0.05） as well as of sIL-6R in both vitiliginous and non-vitiliginous skin compared with the successfully treated patients. The level of IL-6 in the suction blister fluid from both vitiliginous and non-vitiliginous skin was significantly higher in patients with vitiligo stable for less than one year than in those stable for one or more years （（148.46 ± 88.00） vs. （93.54 ± 71.07） ng/L, P < 0.05; （114.82 ± 64.66） vs. （67.40 ± 25.23） ng/L, P < 0.01）, but no significant differences were observed for the level of sIL-6R in vitiliginous or non-vitiliginous skin between the two groups of patients （both P > 0.05）. Decreased blister fluid level of IL-6 was observed in vitiliginous skin from patients with segmental vitiligo compared with those with non-segmental vitiligo （（77.33 ± 61.70） vs. （131.68 ± 84.54） ng/L, P < 0.05）, but there was no significant difference in the level of IL-6 in non-vitiliginous skin or the level of sIL-6R in vitiliginous and non-vitiliginous skin between the patients with segmental vitiligo and those with non-segmental vitiligo （all P > 0.05）. Moreover, significant differences were observed in the level of IL-6 in vitiliginous skin （（96.27 ± 53.390） vs. （178.90 ± 96.48） ng/L, P < 0.01） and non-vitiliginous skin （（78.25 ± 40.30） vs. （107.02 ± 42.48） ng/L, P < 0.05）, but not in the level of sIL-6R （both P > 0.05） in vitiliginous or non-vitiliginous skin, between the successfully and unsuccessfully treated patients with non-segmental vitiligo. Conclusions The abnormal expression of IL-6 may somewhat affect the microenvironment in vitiliginous lesions of patients, which seems to be associated with the efficacy of autologous cultured melanocyte transplantation.